RecruitingPhase 2NCT06455293

Psilocybin Therapy for Depression in Parkinson's Disease

The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease


Sponsor

Joshua Woolley, MD, PhD

Enrollment

60 participants

Start Date

Aug 19, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.


Eligibility

Min Age: 40 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether psilocybin (a compound found in certain mushrooms) can help reduce depression in people who have Parkinson's disease. Researchers want to understand if this type of therapy is safe and effective for this specific group. **You may be eligible if...** - You are between 40 and 80 years old - You have been diagnosed with Parkinson's disease by a neurologist - Your Parkinson's is in an early-to-moderate stage (stages 1–3) - You are currently experiencing symptoms of depression - You are comfortable speaking and writing in English - You can travel to UCSF for in-person visits and join virtual appointments - You have an active doctor (primary care, neurologist, or psychiatrist) managing your care **You may NOT be eligible if...** - You are experiencing psychosis or have lost touch with reality - You have significant memory or thinking problems - You take medications that could interact badly with psilocybin - You have a health condition that makes participation unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPsilocybin

Single dose of psilocybin ranging from low ("microdose") to high delivered orally in two separate drug administration sessions with psychological support and monitoring.

DRUGPimavanserin

Participants will receive either pimavanserin or placebo during their drug administration sessions.


Locations(1)

University of California, San Francisco

San Francisco, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06455293


Related Trials